Five months into Utah’s Doctronic AI prescription renewal pilot, the state hasn’t had to hit the emergency stop. Doctronic has filed two monthly compliance reports showing zero serious safety incidents. That’s the early data Utah’s Office of Artificial Intelligence Policy just released.

Doctronic’s AI can recommend renewals for 192 drugs covering chronic conditions including hypertension, diabetes, and depression. The program launched in mid-December is still in Phase 1: a licensed physician must authorize every AI recommendation before it reaches a pharmacy. The state won’t advance to Phase 2 until Doctronic logs 250 approved renewals per drug group, not the original 250-prescription total. Two drugs, Butalbital and Flecainide, were pulled from the formulary post-launch.

The clean safety record doesn’t mean everyone’s aligned. Utah’s Medical Licensing Board called for the program’s suspension. Their concern isn’t abstract: every prescription renewal is a clinical touchpoint where a physician can catch a new symptom, a drug interaction, or a worsening condition. Stanford Law researchers flagged this structural risk, noting that automating renewals removes opportunities for broader patient assessment, even when individual refills look routine.

Here’s what operators should read: if this 12-month pilot completes without a reportable incident, Utah just handed every state with a regulatory sandbox a live template. The state is explicitly publishing results for federal regulators and other states to calibrate governance. Third-party red teaming found potential vulnerabilities, which Utah disclosed, but says guardrails protect typical users. That disclosure posture is what sandbox access costs — founders building health AI in other states need to budget for it.

Phase 1 physician review isn’t optional, and the per-drug-group threshold means separate compliance tracking for each formulary bucket. More engineering hours than the headlines suggest.

The 12-month data release is the real vote. The board is watching.

— Nathan Zakhary